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Background: We aimed to evaluate the safety and efficacy of TS-1 adjuvant chemotherapy in Taiwanese patients with
gastric cancer.
Methods:We included in this study patients with locally advanced gastric cancer who received adjuvant TS-1 or 5-fluorouracil
chemotherapy after curative surgery and extended lymph node dissection between 1 June 2008 and 31 December 2012 at
Chang Gung Memorial Hospital. Patient characteristics, tumor features, safety profiles and compliance with TS-1 treatment were
retrospectively analyzed from medical charts.
Results: Forty patients received adjuvant chemotherapy with TS-1 and 193 with 5-fluorouracil within the study period.
The 1- and 2-year overall survival rates were 90.6% and 87% in the TS-1 group and 95.4% and 86.8% in the 5-fluorouracil
group (P= 0.34). The 1- and 2-year disease-free survival rates were 90.6% and 74.7% in the TS-1 group and 88% and 75.7%
in the 5-fluorouracil group (P= 0.66). In the TS-1 group, tumor recurrence was more frequent in those with >15 metastatic
lymph nodes than ≤15. Overall, 78.9%, 74.3%, 62.1% and 56% of patients underwent TS-1 treatment for at least 3, 6, 9 and
12 months, respectively. The most common adverse events of TS-1 were skin hyperpigmentation (55%), diarrhea (27.5%),
dizziness (27.5%) and leucopenia (20%). Severe adverse events (SAEs; grade III or IV toxicity) were diarrhea (7.5%), stomatitis
(7.5%), leukopenia (5%), vomiting (2.5%), anorexia (2.5%) and dizziness (2.5%). Patients who underwent total gastrectomy had
a significantly greater risk of TS-1-related SAEs than patients who underwent subtotal gastrectomy (40% versus 8%, P= 0.014).
Conclusions: The incidence of SAEs during TS-1 therapy was more common in Taiwanese patients with gastric cancer who
underwent total gastrectomy compared with those who underwent subtotal gastrectomy. Clinicians must be aware of and
able to manage these SAEs to maximize patient compliance with adjuvant TS-1.
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Gastric cancer is the fourth most common cancer and
the second most common cause of cancer death world-
wide. In 2008, there were an estimated 989,600 new gastric
cancer cases and 738,000 deaths worldwide [1]. In Taiwan,* Correspondence: js1101@adm.cgmh.org.tw
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reproduction in any medium, provided the orgastric cancer is the sixth leading cause of cancer-related
mortality, causing approximately 2,446 patient deaths in
2009 [2]. Surgical resection is the only curative modality
for gastric cancer. Extended (D2) lymph node dissection is
considered a standard modality for curative gastrectomy
among experienced surgeons worldwide [3-5]; however,
approximately 25% to 40% of patients experience tumor
recurrence within 5 years after surgery [3-5]. To overcome
this dilemma, the role of adjuvant chemotherapy in the
treatment of patients with resectable gastric cancer should
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in its advanced stages [6,7]; thus, adjuvant chemotherapy
is often administered to patients with gastric cancer after
curative surgery to prevent tumor recurrence and prolong
survival time. Unfortunately, early clinical trials with vari-
ous adjuvant chemotherapy regimens produced negative
results [8-15]. However, data from meta-analysis studies
[16,17] indicated a significant survival benefit associated
with fluorouracil-based adjuvant chemotherapy. There
was no consensus regarding the optimal adjuvant che-
motherapeutic regimen, schedule or duration of treat-
ment for gastric cancer until the results of three recently
published phase III studies became available after 2007
[18-20]. Tegafur-uracil was the first agent demonstrated
to prolong both overall survival and relapse-free survival
compared to surgery alone in a large phase III randomized
study [18]. This study was terminated before the target
number of patients was reached because accrual was
slower than expected and the benefit was limited in pa-
tients with serosa-negative locally advanced gastric cancer
classified according to the Japanese staging system [21].
The Adjuvant Chemotherapy Trial of TS-1 for Gastric
Cancer (ACTS-GC) was the first well-designed, large-
enrollment phase III study that showed significant
benefit of adjuvant chemotherapy for Japanese patients
with stage II and III gastric cancer who had undergone D2
dissection [19]. Among patients who underwent 1 year
of treatment with TS-1, an oral fluoropyrimidine, the
3-year overall survival rate was 80%, compared to
70.1% in the surgery alone group (P <0.001). The sur-
vival benefit persisted at 5 years [22]. The latest phase
III study examining capecitabine and oxaliplatin com-
bination treatment (CLASSIC study) in stage II to III
stomach cancer after D2 resection [20] was reported
in January 2012. The primary end-point (3-year disease-
free survival) was achieved in 74% of patients in the
chemotherapy group and in 59% of patients in the sur-
gery alone group (P <0.0001). However, 3-year overall
survival was not significantly different between the two
groups (83% versus 78%; P = 0.0493). Thus, a longer
follow-up period may be needed to demonstrate the
potential survival benefit of capecitabine and oxalipla-
tin combination treatment.
Until now, TS-1 has been the only effective adjuvant
chemotherapy agent known to prolong disease-free sur-
vival and overall survival in patients with stage II and III
gastric cancer. TS-1 has been available in Taiwan since
2007. Depending on the patient’s preference and the
clinician’s decision, TS-1 could be used as an adjuvant
treatment for patients with gastric cancer after curative
D2 dissection in clinical practice. This study aimed to
evaluate the safety and efficacy of TS-1 as adjuvant
chemotherapy for the treatment of gastric cancer in
Taiwanese populations.Methods
Patient selection
We retrospectively selected patients with gastric cancer
who received TS-1 as adjuvant chemotherapy after cura-
tive gastrectomy between 1 June 2008 and 31 December
2012 at Chang Gung Memorial Hospital (Linkou branch),
Taoyuan, Taiwan. The decision on performing either a
total or subtotal gastrectomy was determined by the sur-
geon, based on tumor location, histological type and free
resection margin. All patients achieved microscopic tumor
clearance (R0), underwent resection with D2 lymph node
dissection, and received TS-1 in an adjuvant setting.
Patients with a histological diagnosis other than adeno-
carcinoma or poorly differentiated carcinoma and those
who received other antitumor treatments (radiotherapy
or other chemotherapeutic agents) were excluded from
the analysis. Information regarding demographic data,
tumor stage, tumor histology, surgery method and ad-
verse events during TS-1 treatment was retrospectively
obtained from medical charts. Patients diagnosed with
gastric cancers who underwent curative gastrectomy and
D2 lymph node dissection, and received intravenous
5-fluorouracil (5FU) adjuvant therapies in the same time
period were retrospectively included to compare the
efficacy between different adjuvant chemotherapies. The
tumor stage was determined according to the American
Joint Committee on Cancer (AJCC) Cancer Staging
Manual (6th edition) [23]. The grading of adverse events
was performed according to the Common Terminology
Criteria for Adverse Events, version 3.0. All patients
were followed-up until 31 December 2012. The study
was approved by the ethics committee of the institute.
Adjuvant chemotherapy treatment
When possible, patients would receive adjuvant treat-
ment within 6 weeks after surgery. For TS-1 administra-
tion, patients with a body surface area <1.25 m2 received
80 mg daily, those with a body surface area ≥1.25 m2
and <1.5 m2 received 100 mg daily, and those with a
body surface area of ≥1.5 m2 received 120 mg daily. A
TS-1 capsule was given orally twice daily from day 1 to
day 28 for 42 days per cycle. The planned treatment
duration was nine cycles. Dose escalation or schedule
modification occurred depending on the clinician’s
decision to minimize adverse effects. The TS-1 com-
pliance at each given time was determined by the fol-
lowing formula: (number of patients who received TS-1
treatment - number of patients who withdrew at the
given time) ∕ number of patients who received TS-1 treat-
ment at the given time period. Patients who withdrew from
TS-1 treatment owing to tumor relapse were excluded in
the TS-1 compliance calculation for any given time.
In Taiwan, an intravenous 5FU-based regimen is the
standard adjuvant chemotherapy for patients with gastric
Table 1 Clinical characteristics of patients with gastric








Total 40 (100) 193 (100)
Male gender 24 (60) 123 (63.7) 0.39
Median age (range) 61.0 (27 to 88) 61.1 (27 to 90) 0.63
ECOG performance
status scale
0 32 (80) 133 (68.9) 0.24
1 7 (17.5) 47 (24.4)
2 1 (2.5) 13 (6.7)
Histological type
Intestinal 15 (37.5) 61 (31.6) 0.29
Diffuse 25 (62.5) 132 (68.4)
Gastrectomy method
Subtotal 25 (62.5) 124 (64.2) 0.48
Total 15 (37.5) 69 (35.8)
TNM stage
(AJCC, 6th)
Ib 5 (12.5) 48 (24.9) 0.12
II 17 (42.5) 46 (23.8)
IIIa 8 (20) 51 (26.4)
IIIb 2 (5) 13 (6.7)




T1 6 (15) 45 (23.3)
T2 22 (55) 68 (35.2)
T3 9 (22.5) 59 (30.6)
T4 3 (7.5) 21 (10.9)
Nodal stage
(AJCC, 6th)
N0 2 (5) 28 (14.5) 0.28
N1 23 (57.5) 97 (50.3)
N2 9 (22.5) 50 (25.9)
N3 6 (15) 18 (9.3)
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative
Oncology Group; TNM, Tumor-node-metastasis.
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National Health Insurance [24]. In our institute, adju-
vant treatment for gastric patients followed the Roswell
Park regimen [25], which is detailed as six courses of
intravenous infusion of 5FU 500 mg/m2 and leucovorin
500 mg/m2 over a 2-hour period every week within
8 weeks per cycle. The planned completion of treatment
was a total of four cycles.
Statistical analysis
SPSS 17.0 (SPSS Inc., Chicago, IL, USA) was used for statis-
tical analysis. Clinical characteristics data were summarized
as n (%) for categorical variables and medians with ranges
for continuous variables. Patients’ demographic data
and the frequency of grade III and IV toxicity was tabu-
lated as n (%) by clinical variables, and the data were
compared using the chi-squared (χ2) test, or the Fisher’s
exact test if the number in any cell was less than five.
Overall and disease-free survival times were calculated
from the date of surgery to the date of the event. Survival
rates were calculated using the Kaplan-Meier method. Uni-
variate analysis of survival for all clinical characteristics was
performed using the log-rank test and Cox’s proportional
hazard model. Data of patients who were lost to follow-up
were censored for the analysis of overall and disease-free
survival. All statistical assessments were considered sig-
nificant at P <0.05.
Results
Our study included 40 patients who received adjuvant
chemotherapy with TS-1 and 193 with 5FU. Their basic
demographic data are summarized in Table 1. In the
TS-1 group, the median age was 61 years (range, 27 to
88), and 60% (24) were men. Thirty-nine patients (96%)
had an excellent Eastern Cooperative Oncology Group
performance status (grade 0 or 1). Diffuse-type and
intestinal-type gastric cancers were noted in 25 and 15
patients, respectively. Fifteen patients underwent total
gastrectomy, and the remaining 25 patients underwent
subtotal gastrectomy. There was no significant differ-
ence in patients received TS-1 treatment between types
of curative surgery they received when comparing each
subcategory of age, gender, tumor histological type, and
T or N stage of the sixth edition AJCC staging system
(data not shown). Based on the AJCC staging system
(sixth edition), five patients were at stage Ib, seventeen
were at stage II, eight were at stage IIIa, two were at
stage IIIb, and eight were at stage IV. All stage IV patients
were M0 status, five patients had N3 diseases, two had T4
diseases and one patient had N3 and T4 disease. There
was no significant difference in clinical characteristics
between the TS-1 and 5FU treatment groups.
By the end of December 2012, the median follow-up
duration was 627 days (range, 178 to 1,711) in TS-1treatment group. Eight patients experienced tumor recur-
rence, six of whom during treatment and two after treat-
ment completion. Four of these patients died from
cancer-related mortality (morbidities) at the end of the
study. No treatment-related mortality was observed.
The cumulative overall and disease-free survival curves
of patients receiving adjuvant treatment with either TS-1
Table 2 TS-1 dose modification and compliance of
patients with gastric cancer
n (%)
Received treatment schedule modification 18 (45)
Underwent dose de-escalation 6 (15)
Discontinued TS-1 treatment at study end 31 (77.5)
Reasons for discontinuation
Completion of TS-1 treatment 14 out of 31 (45)
Toxicity 9 out of 31 (29)
Tumor recurrence 6 out of 31 (19)
Economic factors 2 out of 31 (6)
TS-1 treatment duration (compliance)
At least 3 months 30 out of 38 (78.9)
At least 6 months 26 out of 35 (74.3)
At least 9 months 18 out of 29 (62.1)
Completed nine full cycles 14 out of 25 (56)
The median TS-1 treatment duration was 226 days (range 7 to 400). TS-1 compli-
ance: the number of patients who discontinued treatment because of toxicity or
economic factor subtracted from the number of patients who underwent TS-1
treatment at the given time. Patients who withdrew from TS-1 treatment owing
to tumor relapse were excluded in the TS-1 compliance calculation for any
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all survival rates were 90.6% and 87% in the TS-1 group
and 95.4% and 86.8% in the 5FU group. There was no
significant difference in overall survival (P = 0.34) and
disease-free survival (P = 0.66) between the TS-1 and
5FU group.
Patient compliance with TS-1 is summarized in Table 2.
The median TS-1 treatment duration was 226 days (range,
7 to 400). TS-1 schedule modification was noted in 18 pa-
tients, and six patients underwent TS-dose de-escalation.
Nine patients continued with TS-1 treatment until the
end of the study. The reasons for discontinuation included
completion of TS-1 treatment course (14 out of 31, 45%),
toxicity (9 out of 31, 29%), recurrent cancer (6 out of 31,
19%) and economic factors (2 out of 31, 6%). Overall,
78.9%, 74.3%, 62.1% and 56% of patients continued TS-1
treatment for at least 3, 6, 9 and 12 months, respectively.
We assessed the incidence of adverse events associated
with TS-1 in all patients (n = 40; Table 3). The most
common adverse events were skin hyperpigmentation
(55%), diarrhea (27.5%), dizziness (27.5%) and leucopenia
(20%). Grade III adverse events included diarrhea (5%),Figure 1 Survival rates of patients with gastric cancer receiving
either TS-1 or 5-fluorouracil adjuvant treatment. (a) Cumulative
overall survival and (b) disease-free survival.
given time.stomatitis (7.5%), leukopenia (5%), vomiting (2.5%), an-
orexia (2.5%) and dizziness (2.5%). Only one grade IV
adverse event was observed in this study (diarrhea, 2.5%).
Table 4 summarizes predictive factors for 2-year disease-
free survival and grade III or IV toxicity in patients re-
ceiving TS-1. There was a significant difference between
patients with >15 metastatic lymph nodes (N3 stage)
and ≤15 metastatic lymph nodes (N0 to N2 stage) in
their 2-year disease-free survival (17% versus 91%; hazard
ratio 0.09; 95% confidence interval 0.02, 0.40; P <0.001).Table 3 Adverse events experienced by patients receiving
adjuvant TS-1 treatment
Events Patients, n = 40 (%)
Grade I Grade II Grade III Grade IV Total
Skin pigmentation 18 (45) 4 (10) 0 0 22 (55)
Diarrhea 1 (2.5) 7 (17.5) 2 (5) 1 (2.5) 11 (27.5)
Fatigue 1 (2.5) 2 (5) 0 0 3 (7.5)
Vomiting 3 (7.5) 2 (5) 1 (2.5) 0 6 (15)
Stomatitis 0 2 (5) 3 (7.5) 0 5 (12.5)
Anorexia 5 (12.5) 1 (2.5) 1 (2.5) 0 7 (17.5)
Alopecia 3 (7.5) 0 0 0 3 (7.5)
Dizziness 8 (20) 2 (5) 1 (2.5) 0 11 (27.5)
Leukopenia 1 (2.5) 5 (12.5) 2 (5) 0 8 (20)
Thrombocytopenia 2 (5) 0 0 0 2 (5)
Anemia 1 (2.5) 4 (10) 0 0 5 (12.5)
Table 4 Predictive factors for 2-year disease-free survival rate and grade III or IV toxicity in patients with gastric cancer
who underwent adjuvant TS-1 treatment
Variables 2-year disease-free
survival rate
P Grade III or IV toxicity
n (%)
P
Gender Male (n = 24) 75% 0.68 6 (25.0) 0.33
Female (n = 16) 74% 2 (12.5)
Age ≥65 (n = 13) 82% 0.29 1 (7.7) 0.18
<65 (n = 27) 50% 7 (25.9)
Histological type Diffuse type (n = 25) 74% 0.57 6 (24.0) 0.41
Intestinal type (n = 15) 75% 2 (13.3)
ECOG performance status scale 0 (n = 32) 74% 0.63 6 (18.8) 0.74
1 to 2 (n = 8) 75% 2 (25.0)
Type of gastrectomy Total (n = 15) 72% 0.66 6 (40.0) 0.014
Subtotal (n = 25) 76% 2 (8.0)
T stage 1 to 2 (n = 28) 82% 0.44 6 (21.4) 0.73
3 to 4 (n = 12) 75% 2 (16.7)
Lymph node metastases numbers 0 to 15 (n = 34) 91% <0.001 0 (0) 0.18
>15 (n = 6) 17% (HR 0.09, 95% CI 0.02, 0.40) 8 (23.5)
CI: confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.
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nificantly greater risk of grade III or IV toxicities associ-
ated with TS-1 compared with patients who underwent
subtotal gastrectomy (40% versus 8%, P = 0.014). There
was no difference in 2-year disease-free survival and ser-
ious adverse events in the TS-1 treatment group when
comparing between patients’ age, gender, performance
status scale, cancer histological type or tumor stage.
Discussion
In this study, we collected data from a single institution
regarding compliance, adverse events and efficacy of
adjuvant TS-1 therapy for Taiwanese populations with
gastric cancer after curative surgery and D2 lymph
node dissection. Although the number of patients in-
cluded was small, the data are representative of patients
with gastric cancer treated with adjuvant TS-1 therapy.
TS-1 adjuvant treatment efficacy is comparable to a
Roswell Park regimen in terms of overall survival and
disease-free survival.
The majority of adverse events associated with TS-1
were mild and manageable in this study; toxicities of the
gastrointestinal tract (diarrhea (7.5%), stomatitis (7.5%)
and vomiting (2.5%)) and hematologic toxicity with
leukopenia (5%) constituted the most common grade III
and IV toxicities related to TS-1. In the ACTS-GC study,
the most common grade III and IV toxicities were
anorexia (6%), nausea (3.7%) and diarrhea (3.1%); only
1.2% of patients experienced grade III leukopenia. A diverse
array of toxicities related to TS-1 has been reported among
different ethnicities. Two phase I studies of TS-1 concluded
that myelosuppression was the most severe dose-relatedtoxicity and recommended an 80 to 120 mg daily dose of
TS-1 in Japanese patients [26,27]. Four phase I studies
from the US and the Netherlands concluded that diarrhea
was the most severe dose-related toxicity and recom-
mended a TS-1 dose of 50 to 80 mg in Caucasian popula-
tions [28-31]. A larger 5FU area under the curve was
noted in Caucasian patients compared with Japanese
patients given the same TS-1 dose, which partially ex-
plained the different toxicity profiles [32]. The pharma-
cokinetic profiles of TS-1 in Taiwanese populations were
comparable with those from Japanese and other Asian
populations [26,27]. The minor difference in toxicity
profiles between the current study and the ATCS-GC
study may be explained by historical comparison and retro-
spective bias in data collection in our study. Our findings
indicate that in Asian patients who receive daily TS-1 treat-
ment, clinicians should pay attention to gastrointestinal
toxicity, including diarrhea, stomatitis and vomiting, and
should manage them early and properly with medications
and dose or schedule modification.
Patient compliance with TS-1 throughout the duration
of treatment was 4% to 8% lower than what was reported
throughout the duration of treatment in the ACTS-GS
study [26]. The difference was acceptable and expected
when comparing data from clinical practice with clinical
study [33]. A subgroup analysis [34] from the ACTS-GC
study demonstrated that overall and disease-free survival
times were better in patients who completed 12 months
of TS-1 adjuvant treatment. However, the factors related
to lack of compliance with adjuvant TS-1 chemotherapy
were not well explored. Recent studies by Aoyama et al.
reported that weight loss after surgery (a decrease of
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60 mL/min) were factors related to discontinuation of
TS-1 treatment [35,36]. Tsujimoto et al. reported that
younger patient age and treatment by a senior doctor
(with more than 15 years of experience) were factors as-
sociated with successful completion of 12 months of
TS-1 adjuvant treatment [34].
In the current study, the main reason for early with-
drawal from TS-1 treatment was adverse events. Patients
who underwent total gastrectomy experienced a signifi-
cantly higher incidence of grade III or IV toxicities under
TS-1 therapy in this study. A Korean study that included
305 patients with gastric cancer undergoing TS-1 treat-
ment in the same setting showed that total gastrectomy
was associated with a higher risk of hematologic grade III
and IV toxicities than distal gastrectomy; however, there
was no difference in non-hematologic toxicity [37]. Because
of the rarity of hematologic toxicity and the limited
number of patients, we were unable to address the rela-
tionship between hematologic toxicity and total gas-
trectomy in this study. There were no differences in
the pharmacokinetic profile of TS-1 components in 12
Taiwanese patients with advanced gastric cancer, re-
gardless of whether they underwent gastrectomy [38].
Kinoshita et al. observed a slightly higher incidence of
adverse reactions in adjuvant TS-1 treatment compared
with that in unresectable or recurrent gastric cancer -
the authors concluded the difference was probably due
to the influence of gastrectomy [39]. However, data
regarding the pharmacokinetic profiles of TS-1 com-
ponents in patients who underwent total gastrectomy
or subtotal gastrectomy were lacking. The reason for
the higher incidence of serious adverse events in patients
who underwent total gastrectomy and received TS-1 treat-
ment was unknown. Because of inconsistency in clinical
experience, it is unclear whether total gastrectomy alters
the pharmacokinetic profile of TS-1. An understanding
of the impact of total gastrectomy on TS-1 treatment
will require further study.
In our study, lymph node stage had a significant im-
pact on 2-year disease-free survival, especially in patients
with more than 15 metastatic lymph nodes. In the
ACTS-GC study, less than 6% of enrolled patients had
more than 16 metastatic lymph nodes. The impact of
lymph node metastases on overall survival in TS-1-treated
patients was limited to those with N0 and N1 nodal
stage in subgroup analysis [22]. In the CLASSIC study,
subgroup analysis showed that the greatest chemotherapy
benefit was in patients with N1 and N2 nodal stage [20].
Considering the currently available evidence, adjuvant
TS-1 should be considered as the treatment of choice
for patients with gastric cancer with fewer than eight
metastatic lymph nodes, whereas capecitabine and oxa-
liplatin should be the treatment of choice for patientswith 1 to 15 metastatic lymph nodes. In line with the
ACTS-GC study, our study does not lead us to recom-
mend adjuvant TS-1 treatment for patients with gastric
cancer who have >15 metastatic lymph nodes.
The current study had some limitations. First, we were
only able to include a small number of patients. With a
limited follow-up period and a non-randomized design
in comparison to adjuvant 5FU treatment, the efficacy of
TS-1 in treating gastric cancer in the adjuvant setting
could not be accurately addressed. Being a novel agent,
treatment with TS-1 is not yet covered by the National
Health Insurance in Taiwan. Thus, patients are respon-
sible for paying the fee. The price for a 20 mg pill of
TS-1 is US$11.40. The cost becomes US$11,525 to
US$17,287 assuming a dose of 80 to 120 mg daily over
the full duration of treatment. Because of this financial
burden, few patients are able to receive TS-1 as adjuvant
chemotherapy for gastric cancer treatment. Second, based
on a retrospective data collection in the current study, the
safety profile of TS-1 was under-assessed, and because
only a small number of patients was included, the inci-
dence of severe adverse effects due to TS-1 could not be
evaluated. In the future, nationwide studies are necessary
to address these limitations. As more results become avail-
able from various clinical trials focusing on different solid
tumors, clinicians and patients will become more in-
formed and familiar with the safety profile of TS-1.Conclusions
TS-1 is easy to administer on an outpatient basis and is
the only adjuvant regimen shown to improve overall sur-
vival and disease-free survival in patients with gastric
cancer. Diarrhea, stomatitis and vomiting were the most
common grade III and IV toxicities in patients with gastric
cancer who were receiving adjuvant TS-1. The incidence
of grade III and IV toxicities associated with TS-1 was
more common in patients who underwent total gastrec-
tomy. Clinicians must have the awareness and knowledge
to manage these grade III and IV toxicities to maximize
patient compliance with adjuvant TS-1.Abbreviations
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